# Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer

> **NCT00540514** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 1052 (actual)

## Conditions studied

- Non-Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Albumin-bound paclitaxel
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00540514
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11-01
- **Primary completion:** 2009-10-01
- **Final completion:** 2013-02-01
- **Target enrollment:** 1052 (ACTUAL)
- **Last updated:** 2019-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00540514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00540514, "Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00540514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*